Evidence map›Paper›PMID 38384471›Full record

ReviewFrontiers in immunology2024

Epstein-Barr virus: the mastermind of immune chaos.

Jean de Melo Silva, Carlos Eduardo de Castro Alves, Gemilson Soares Pontes

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Frontiers in immunology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 64 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
64citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

64 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. TLR2 and TLR9 in Brain Cancer Patients in Relation to EBV Status.International journal of molecular sciences · 2026
    Article
  3. Review
  4. Review
  5. Article
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Observational
  13. Review
  14. EBV Triggers a Distinct Antiviral Response in HMC3 Cells.bioRxiv : the preprint server for biology · 2026
    Article
  15. Article
  16. Review
  17. Article
  18. Review
  19. Article
  20. Review

4 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Jean de Melo SilvaLaboratory of Virology and Immunology, National Institute of Amazonian Research (INPA), Manaus, AM, Brazil.
Carlos Eduardo de Castro AlvesLaboratory of Virology and Immunology, National Institute of Amazonian Research (INPA), Manaus, AM, Brazil.
Gemilson Soares PontesLaboratory of Virology and Immunology, National Institute of Amazonian Research (INPA), Manaus, AM, Brazil.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The Epstein-Barr virus (EBV) is a ubiquitous human pathogen linked to various diseases, including infectious mononucleosis and multiple types of cancer. To control and eliminate EBV, the host's immune system deploys its most potent defenses, including pattern recognition receptors, Natural Killer cells, CD8

Indexed as

Epstein-Barr Virus InfectionsInfectious MononucleosisHerpesvirus 4, HumanHumansReceptors, Pattern RecognitionT-LymphocytesReceptors, Pattern Recognitionacquired immunityEBVevasionherpesvirusinnate immunity

Identifiers

PMID38384471
PMCPMC10879370

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.